{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:24:58Z","timestamp":1793330698975,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03622-3","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:47:04Z","timestamp":1778312824000},"page":"3165-3186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Antonio","family":"Tursi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Elisei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida","family":"Barberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giammarco","family":"Mocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo V.","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"de Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Maconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cataletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Marzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Monterubbianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"di Fonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Patturelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Giuseppe","family":"Ribaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Bertani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rodino\u2019","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislava","family":"Sebkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Bodini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pranzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaelena","family":"Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Scarcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Luppino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ferronato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Spagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Luzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta Gerarda","family":"Gravina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Vespere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sedda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Allegretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libera","family":"Fanigliulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurino","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Forti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Neve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Piergallini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Scarozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Bevevino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Iacopini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Gaiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Kayali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Mucherino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"D\u2019antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berardino","family":"D\u2019ascoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bachetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Giorgetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Pagnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Donnarumma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Onidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Usai","family":"Satta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Picchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-7298","authenticated-orcid":false,"given":"Alfredo","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Italian Network for Inflammatory Bowel Diseases (IN-IBD)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Lorenzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Zingone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Checchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrio","family":"Bassotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Zampaletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giovanna","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carla","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Pica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Zippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cassieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Lorenzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Zerboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serafina","family":"Fiorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Montesano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido Daniele","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Della","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Tonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia Immacolata","family":"Cazzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Scorza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Catarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Di Bartolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"3622_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of Ulcerative Colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649\u201370. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx008.","journal-title":"J Crohns Colitis"},{"key":"3622_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in Ulcerative Colitis: medical treatment. J Crohns Colitis. 2022;16:2\u201317. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab178.","journal-title":"J Crohns Colitis"},{"key":"3622_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","volume":"33","author":"S Ben-Horin","year":"2011","unstructured":"Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease. Aliment Pharmacol Ther. 2011;33:987\u201395. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04612.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"3622_CR4","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.dld.2017.07.010","volume":"49","author":"JO Lindsay","year":"2017","unstructured":"Lindsay JO, Armuzzi A, Gisbert JP, et al. Indicators of suboptimal tumor necrosis factor antagonist therapy in Inflammatory bowel disease. Dig Liver Dis. 2017;49:1086\u201391. https:\/\/doi.org\/10.1016\/j.dld.2017.07.010.","journal-title":"Dig Liver Dis"},{"key":"3622_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","volume":"4","author":"NA Kennedy","year":"2019","unstructured":"Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4:341\u201353. https:\/\/doi.org\/10.1016\/S2468-1253(19)30012-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3622_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.tips.2016.10.014","volume":"38","author":"M Coskun","year":"2017","unstructured":"Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for Inflammatory bowel disease. Trends Pharmacol Sci. 2017;38:127\u201342. https:\/\/doi.org\/10.1016\/j.tips.2016.10.014.","journal-title":"Trends Pharmacol Sci"},{"issue":"Suppl 2","key":"3622_CR7","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii111-115. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202576.","journal-title":"Ann Rheum Dis"},{"key":"3622_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/25785826.2023.2195522","volume":"46","author":"H Nakase","year":"2023","unstructured":"Nakase H. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of Ulcerative Colitis for future positioning in Inflammatory Bowel Disease treatment. Immunol Med. 2023;46:121\u201330. https:\/\/doi.org\/10.1080\/25785826.2023.2195522.","journal-title":"Immunol Med"},{"key":"3622_CR9","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for Ulcerative Colitis. N Engl J Med. 2017;376:1723\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1606910.","journal-title":"N Engl J Med"},{"key":"3622_CR10","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV, et al. Filgotinib as induction and maintenance therapy for Ulcerative Colitis (SELECTION): A phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00666-8.","journal-title":"Lancet"},{"key":"3622_CR11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active Ulcerative Colitis: Results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(22)00581-5.","journal-title":"Lancet"},{"key":"3622_CR12","unstructured":"Regime di rimborsabilit\u00e0 e prezzo, a seguito di nuove indicazioni terapeutiche, del medicinale per uso umano \u201cXeljanz\u201d. Gazzetta ufficiale della repubblica Italiana del 17.12.2020; Serie generale n. 312: 24\u201329 n.d. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2020-12-17&atto.codiceRedazionale=20A06818&elenco30giorni=false (accessed November 25, 2025)."},{"key":"3622_CR13","unstructured":"Regime di rimborsabilit\u00e0 e prezzo, a seguito di nuove indicazioni terapeutiche, del medicinale per uso umano \u201cRinvoq\u201d. GAZZETTA UFFICIALE DELLA REPUBBLICA ITALIANA del 15.07.2023; Serie generale n. 58: 51\u201356 n.d. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2023-07-15&atto.codiceRedazionale=23A04022&elenco30giorni=false (accessed November 25, 2025)."},{"key":"3622_CR14","unstructured":"Regime di rimborsabilita\u2019 e prezzo a seguito di nuove indicazioni terapeutiche e riclassificazione del medicinale per uso umano \u00abJyseleca\u00bb ai sensi dell\u2019art. 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 105\/2023). (23A01342) Gazzetta Ufficiale della Repubblica Italiana, Serie generale n\u00b058 del 09\u201303\u20132023, pp 39\u201341. n.d. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2023-03-09&atto.codiceRedazionale=23A01342&elenco30giorni=false (accessed November 25, 2025)."},{"key":"3622_CR15","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1080\/14656566.2023.2230126","volume":"24","author":"A Tursi","year":"2023","unstructured":"Tursi A, Mocci G, Cingolani L, et al. Use of Tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study. Expert Opin Pharmacother. 2023;24:1649\u201356. https:\/\/doi.org\/10.1080\/14656566.2023.2230126.","journal-title":"Expert Opin Pharmacother"},{"key":"3622_CR16","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2025.00067","author":"A Tursi","year":"2025","unstructured":"Tursi A, Mocci G, Costa F, et al. Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study. Intest Res. 2025. https:\/\/doi.org\/10.5217\/ir.2025.00067.","journal-title":"Intest Res"},{"key":"3622_CR17","doi-asserted-by":"publisher","unstructured":"Mocci Md Frcp G, Scaldaferri F, Napoltitano D, et al. P0634 Upadacitinib effectiveness and safety in patients with ulcerative colitis: data from a real-world study. J Crohn\u2019s Colitis 2025;19:i1249\u2013i1249. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0808.","DOI":"10.1093\/ecco-jcc\/jjae190.0808"},{"key":"3622_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/ibd\/izad037","volume":"30","author":"X Lu","year":"2024","unstructured":"Lu X, Zhou Z-Y, Xin Y, et al. Matching-adjusted indirect comparisons of Filgotinib vs. Vedolizumab, Tofacitinib, and Ustekinumab for moderately to severely active ulcerative colitis. Inflamm Bowel Dis. 2024;30:64\u201377. https:\/\/doi.org\/10.1093\/ibd\/izad037.","journal-title":"Inflamm Bowel Dis"},{"key":"3622_CR19","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002746","author":"RS Dalal","year":"2024","unstructured":"Dalal RS, Kallumkal G, Cabral HJ, Barnes EL, Allegretti JR. One-year comparative effectiveness of Upadacitinib vs. Tofacitinib for Ulcerative Colitis: a multicenter cohort study. Am J Gastroenterol. 2024. https:\/\/doi.org\/10.14309\/ajg.0000000000002746.","journal-title":"Am J Gastroenterol"},{"key":"3622_CR20","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/jcpt.13622","volume":"47","author":"Y Li","year":"2022","unstructured":"Li Y, Yao C, Xiong Q, et al. Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. J Clin Pharm Ther. 2022;47:851\u20139. https:\/\/doi.org\/10.1111\/jcpt.13622.","journal-title":"J Clin Pharm Ther"},{"key":"3622_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad009","volume":"5","author":"R Panaccione","year":"2023","unstructured":"Panaccione R, Collins EB, Melmed GY, et al. Efficacy and safety of advanced therapies for moderately to severely active Ulcerative Colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis. Crohns Colitis 360. 2023;5:otad009. https:\/\/doi.org\/10.1093\/crocol\/otad009.","journal-title":"Crohns Colitis 360"},{"key":"3622_CR22","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/apt.18406","volume":"61","author":"S Akiyama","year":"2025","unstructured":"Akiyama S, Shimizu H, Tamura A, et al. Comparative efficacy and safety of three Janus kinase inhibitors in ulcerative colitis: a real-world multicentre study in Japan. Aliment Pharmacol Ther. 2025;61:524\u201337. https:\/\/doi.org\/10.1111\/apt.18406.","journal-title":"Aliment Pharmacol Ther"},{"key":"3622_CR23","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology"},{"key":"3622_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:161\u201370. https:\/\/doi.org\/10.1016\/S2468-1253(21)00377-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3622_CR25","doi-asserted-by":"publisher","first-page":"464","DOI":"10.5217\/ir.2024.00148","volume":"23","author":"M Ikenouchi","year":"2025","unstructured":"Ikenouchi M, Fukui H, Yagi S, et al. Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor \u03b1 antibody. Intest Res. 2025;23:464\u201374. https:\/\/doi.org\/10.5217\/ir.2024.00148.","journal-title":"Intest Res"},{"key":"3622_CR26","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/ueg2.12704","volume":"12","author":"A Nogami","year":"2024","unstructured":"Nogami A, Asonuma K, Okabayashi S, et al. Real-world comparative effectiveness and safety of Filgotinib and Upadacitinib for ulcerative colitis: a multicentre cohort study. United European Gastroenterol J. 2024;12:1357\u201366. https:\/\/doi.org\/10.1002\/ueg2.12704.","journal-title":"United European Gastroenterol J"},{"key":"3622_CR27","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","volume":"21","author":"S Friedberg","year":"2023","unstructured":"Friedberg S, Choi D, Hunold T, et al. Upadacitinib is effective and safe in both ulcerative colitis and Crohn\u2019s disease: prospective real-world experience. Clin Gastroenterol Hepatol. 2023;21:1913-1923.e2. https:\/\/doi.org\/10.1016\/j.cgh.2023.03.001.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3622_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13247804","volume":"13","author":"B Farkas","year":"2024","unstructured":"Farkas B, Bessissow T, Limdi JK, et al. Real-world effectiveness and safety of selective JAK inhibitors in ulcerative colitis and Crohn\u2019s disease: a retrospective, multicentre study. J Clin Med. 2024;13:7804. https:\/\/doi.org\/10.3390\/jcm13247804.","journal-title":"J Clin Med"},{"key":"3622_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of Upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23. https:\/\/doi.org\/10.1186\/s41927-018-0031-x.","journal-title":"BMC Rheumatol"},{"key":"3622_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.537","volume":"7","author":"ME Dowty","year":"2019","unstructured":"Dowty ME, Lin TH, Jesson MI, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019;7:e00537. https:\/\/doi.org\/10.1002\/prp2.537.","journal-title":"Pharmacol Res Perspect"},{"key":"3622_CR31","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40262-022-01129-y","volume":"61","author":"F Namour","year":"2022","unstructured":"Namour F, Anderson K, Nelson C, Tasset C. Filgotinib: a clinical pharmacology review. Clin Pharmacokinet. 2022;61:819\u201332. https:\/\/doi.org\/10.1007\/s40262-022-01129-y.","journal-title":"Clin Pharmacokinet"},{"key":"3622_CR32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by Filgotinib, Upadacitinib, Tofacitinib and Baricitinib. Ann Rheum Dis. 2021;80:865\u201375. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219012.","journal-title":"Ann Rheum Dis"},{"key":"3622_CR33","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","volume":"54","author":"F Namour","year":"2015","unstructured":"Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of Filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54:859\u201374. https:\/\/doi.org\/10.1007\/s40262-015-0240-z.","journal-title":"Clin Pharmacokinet"},{"key":"3622_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237186","volume":"13","author":"B Neri","year":"2024","unstructured":"Neri B, Mancone R, Fiorillo M, Schiavone SC, Migliozzi S, Biancone L. Efficacy and safety of Janus Kinase-inhibitors in ulcerative colitis. J Clin Med. 2024;13:7186. https:\/\/doi.org\/10.3390\/jcm13237186.","journal-title":"J Clin Med"},{"key":"3622_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101866","volume":"57","author":"M Attauabi","year":"2023","unstructured":"Attauabi M, Dahl EK, Burisch J, Gubatan J, Nielsen OH, Seidelin JB. Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. EClinicalMedicine. 2023;57:101866. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101866.","journal-title":"EClinicalMedicine"},{"key":"3622_CR36","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.14309\/ajg.0000000000002404","volume":"118","author":"M Dubinsky","year":"2023","unstructured":"Dubinsky M, Bleakman AP, Panaccione R, et al. Bowel urgency in Ulcerative Colitis: current perspectives and future directions. Am J Gastroenterol. 2023;118:1940\u201353. https:\/\/doi.org\/10.14309\/ajg.0000000000002404.","journal-title":"Am J Gastroenterol"},{"key":"3622_CR37","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/ueg2.12686","volume":"12","author":"S Schreiber","year":"2024","unstructured":"Schreiber S, Feagan BG, Louis E, et al. Distinct trajectories of symptomatic response in ulcerative colitis during Filgotinib therapy: a post hoc analysis from the SELECTION study. United European Gastroenterol J. 2024;12:1243\u201355. https:\/\/doi.org\/10.1002\/ueg2.12686.","journal-title":"United European Gastroenterol J"},{"key":"3622_CR38","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/apt.18315","volume":"60","author":"MM Estevinho","year":"2024","unstructured":"Estevinho MM, Sousa-Pinto B, Moreira PL, et al. Network meta-analysis: histologic and histo-endoscopic improvement and remission with advanced therapy in ulcerative colitis. Aliment Pharmacol Ther. 2024;60:1276\u201392. https:\/\/doi.org\/10.1111\/apt.18315.","journal-title":"Aliment Pharmacol Ther"},{"key":"3622_CR39","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/ibd\/izaa289","volume":"27","author":"JR Curtis","year":"2021","unstructured":"Curtis JR, Regueiro M, Yun H, et al. Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM MarketScan\u00ae administrative claims database with Tofacitinib trial data. Inflamm Bowel Dis. 2021;27:1394\u2013408. https:\/\/doi.org\/10.1093\/ibd\/izaa289.","journal-title":"Inflamm Bowel Dis"},{"key":"3622_CR40","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","volume":"159","author":"J Martinez","year":"2023","unstructured":"Martinez J, Manjaly C, Manjaly P, et al. Janus Kinase inhibitors and adverse events of acne: a systematic review and meta-analysis. JAMA Dermatol. 2023;159:1339\u201345. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3830.","journal-title":"JAMA Dermatol"},{"key":"3622_CR41","doi-asserted-by":"publisher","unstructured":"Quraishi MN, Alahmad MA, Swaid TK, Facciorusso A, Grimshaw AA, Al-Bawardy B. Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis. Inflamm Bowel Dis 2026:izag032. https:\/\/doi.org\/10.1093\/ibd\/izag032.","DOI":"10.1093\/ibd\/izag032"},{"key":"3622_CR42","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158:1554-1573.e12. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.001.","journal-title":"Gastroenterology"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03622-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03622-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03622-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:20:46Z","timestamp":1782206446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03622-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3622"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03622-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antonio Tursi has served as a speaker and\/or consultant for AbbVie, AFI, Bayer, Celltrion, Fenix Pharma, Gal\u00e1pagos, Janssen, Omega Pharma, and SILA. Giammarco Mocci served as speaker for and\/or received advisory board fees from AbbVie, Amgen, Aurora Biopharma, Biogen, Celltrion, Chiesi, Fenix Pharma, Ferring, Gal\u00e1pagos, Janssen, MSD, Omega Pharma, Sandoz, Takeda, and Vifor Pharma; Franco Scaldaferri has served as a lecturer for AbbVie, Celltrion, Ferring, Janssen, Lilly, Pfizer, Sanofi, and Takeda. Edoardo Savarino has served as a speaker for AbbVie, AGPharma, Alfasigma, Dr Falk, EG Stada Group, Fresenius Kabi, Grifols, Janssen, Innovamedica, Malesci, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, and Unifarco and has served aa s consultant for Alfasigma, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Dr Falk, Fresenius Kabi, Janssen, Merck & Co, Reckitt Benckiser, Regeneron, Sanofi, Shire, SILA, Sofar, Synformulas GmbH, Takeda, and Unifarco; he received research support from Pfizer, Reckitt Benckiser, SILA, Sofar, and Unifarco; Giovanni Maconi has served as a speaker for and\/or has received advisory board fees from AlfaSigma, Arena, Janssen, Gilead, and Roche; Antonietta Gerarda Gravina has conducted training activities (e.g., ECM, preceptorship) for AbbVie, Biopharma, Fenix Pharma, Gal\u00e1pagos, and Pfizer. Alfredo Papa received speaker fees from AlfaSigma and Janssen. Alfredo Papa is an Editorial Board member of Advances in Therapy. Alfredo Papa was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. Andrea Pasta, Walter Elisei, Brigida Barberio, Caterina De Barba, Giovanni Cataletti, Daniele Napolitano, Francesco Costa, Linda Ceccarelli, Manuela Marzo, Rita Monterubbianesi, Michela Di Fonzo, Giovanni Lombardi, Marta Patturelli, Davide Giuseppe Ribaldone, Lorenzo Bertani, Stefano Rodin\u00f2, Ladislava Sebkova, Giorgia Bodini, Giuseppe Pranzo, Mariaelena Serio, Antonella Scarcelli, Ileana Luppino, Antonio Ferronato, Rocco Spagnuolo, Francesco Luzza, Domenico Morano, Raffaele Pellegrino, Giuliana Vespere, Silvia Sedda, Leonardo Allegretta, Libera Fanigliulo, Laurino Grossi, Fabio Cortellini, Giacomo Forti, Viviana Neve, Simona Piergallini, Patrizio Scarozza, Girolamo Bevevino, Federico Iacopini, Pietro Capone, Federica Gaiani, Stefano Kayali, Caterina Mucherino, Elvira D\u2019antonio, Berardino D\u2019Ascoli, Raffaele Colucci, Francesco Bachetti, Gian Marco Giorgetti, Valeria Clemente, Cristiano Pagnini, Antonio Cuomo, Laura Donnarumma, Francesca Maria Onidi, Paolo Usai Satta, Marcello Picchio have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data were fully anonymized, with no possibility of re-identifying individual patients. The study complied with the Declaration of Helsinki and the determination of the Italian Medicines Agency (20 March 2008). Given its retrospective, non-interventional, and anonymized design, formal ethics committee approval and informed consent were not required according to the AIFA (Agenzia Italiana del Farmaco) Guidelines. Reporting followed STROBE recommendations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}